Keywords: مهارکننده ALK; Alectinib; ALK inhibitor; Ceritinib; EML4-ALK; NSCLC;
مقالات ISI مهارکننده ALK (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Bioanalytical assay for the quantification of the ALK inhibitor lorlatinib in mouse plasma using liquid chromatography-tandem mass spectrometry
Keywords: مهارکننده ALK; ALK; anaplastic lymphoma kinase; EMA; European Medicines Agency; EML4; echinoderm microtubule-associated protein-like 4; ESI; electro spray ionization; FDA; Food and Drug Administration; IS; internal standard; LC-MS/MS; liquid chromatography-tandem mass s
GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors
Keywords: مهارکننده ALK; GCC2-ALK fusion; Next generation sequencing; Targeted therapy; ALK inhibitor; Non-small cell lung cancer;
Design, synthesis and biological evaluation N2-(2-alkyoxy-6-aliphatic aminopyridin-3-yl)-2,4-diaminepyrimidine derivatives bearing acylamino or DBTD 'head' as potential ALK inhibitors
Keywords: مهارکننده ALK; ALK inhibitor; 2,4-diarylaminopyrimidine; Pyridinyl group; DBTD;
Pharmacological inhibition of Anaplastic Lymphoma Kinase rescues spatial memory impairments in Neurofibromatosis 1 mutant mice
Keywords: مهارکننده ALK; Water maze; Spatial memory; Swim speed; Alk inhibitor; Neurofibromatosis; NF1;
Original ArticleThe second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model
Keywords: مهارکننده ALK; Neuroblastoma; ALK inhibitor; Alectinib; PI3K/Akt/mTOR; Apoptosis; NB; neuroblastoma; ALK; anaplastic lymphoma kinase; WT; wild type; dox; doxorubicin; DMSO; dimethyl sulfoxide; FDA; Food and Drug Administration; ALCL; anaplastic large cell lymphoma; NSCL
Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405)
Keywords: مهارکننده ALK; ALK inhibitor; Crizotinib; EML4-ALK; Lung carcinoma; MET;
Ceritinib (LDK378): A Potent Alternative to Crizotinib for ALK-Rearranged Non-Small-Cell Lung Cancer
Keywords: مهارکننده ALK; ALK inhibitor; Clinical trial; Cost-effectiveness; Pharmacokinetics; Resistance;
ALK Testing in Lung Adenocarcinoma: Technical Aspects to Improve FISH Evaluation in Daily Practice
Keywords: مهارکننده ALK; ALK; Fluorescence in situ hybridization; ALK inhibitor; Lung cancer;
Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2)
Keywords: مهارکننده ALK; ABC; ATP-binding cassette; ALK; anaplastic lymphoma kinase; AUC; area under the plasma concentration-time curve; BBB; blood-brain barrier; BCRP; breast cancer resistance protein; Cmax; maximum drug concentration in plasma; EML4; echinoderm microtubule-ass
Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance
Keywords: مهارکننده ALK; NSCLC; ALK; ALK inhibitor; Drug resistance; Alectinib; Xenograft model
A Novel Mechanism of EML4-ALK Rearrangement Mediated by Chromothripsis in a Patient-Derived Cell Line
Keywords: مهارکننده ALK; ALK; Lung cancer; Chromosomal rearrangement; Chromothripsis; ALK inhibitor
Treatment and detection of ALK-rearranged NSCLC
Keywords: مهارکننده ALK; ALK rearrangement; NSCLC; ALK inhibitor; Crizotinib; Diagnosis; Resistance
ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity
Keywords: مهارکننده ALK; ALK; EML4; KIF5B; Fusion gene; Lung cancer; EBUS; TBNA; Crizotinib; ALK inhibitor;